Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aurolab
Latanoprost refrigeration free formulation is developed to overcome difficulties on storing drugs at 2-8˚ C in consumer end and also to avoid risk during transition. This formulation has the best solubilizing agent cyclodextrin to increase the solubility and stability of latanoprost API. To find out the efficacy and safety due to this additional excipient in this formulation rather than the cold storage product the investigators have to perform clinical trial.
Patient has a mean (or median) IOP of 24 and 36 mmHg in at least one eye
Patient has a best corrected ETDRS visual acuity score of +0.6 logMAR (Snellen equivalent of 20/80) or better in each eye.
Patient should have the access / ability to refrigerate study drug.
Residence with 60 kms of Madurai
You may not be if
Patient has a mean (or median) IOP \>36 mmHg in either eye at the Screening Visit.
Patient has a history of or current abnormal corneal sensation or any abnormality in either eye preventing reliable Goldmann applanation tonometry
Pupil in either eye that will not dilate sufficiently for adequate evaluation of the retina
Patient has a history of retinal detachment, proliferative diabetic retinopathy, or any retinal disease in either eye that may be progressive during the study
Patient who has significant ocular symptoms or signs such as photophobia, flashes or streaks of light, metamorphopsia, diplopia, or transient loss of vision in either eye.
Patient has had intraocular surgery (e.g., cataract extraction) in either eye within 4months prior to Screening visit.
Patient is aphakic or has, in the judgement of the investigator, risk for ocular inflammation
Clareo Health | Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost
